Rajeev Mohan, MD
Advanced Heart Failure and Transplant Cardiology · la Jolla, CANPI 1841453081
Payments from drug & device makers
Across 1,024 payments — averaging $458.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$131K
- Boston Scientific$103K
- AstraZeneca$67K
- E.r. Squibb & Sons, L.L.C.$46K
- Bridgebio Pharma, Inc.$31K
- Cvrx, Inc.$31K
- plus $59K from 29 others
Across 1 payment — averaging $300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$300
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 125 | $131,451 |
| Boston Scientific | 64 | $103,328 |
| AstraZeneca | 58 | $67,170 |
| E.r. Squibb & Sons, L.L.C. | 50 | $45,899 |
| Bridgebio Pharma, Inc. | 21 | $31,446 |
| Cvrx, Inc. | 52 | $31,280 |
| Alnylam Pharmaceuticals Inc. | 34 | $24,547 |
| Lexicon Pharmaceuticals, Inc. | 8 | $9,071 |
| Abbott | 163 | $8,306 |
| Bayer | 9 | $6,116 |
| Akcea Therapeutics, Inc. | 6 | $3,527 |
| Medtronic(2 entities) | 49 | $2,044 |
| Actelion Pharmaceuticals US, Inc. | 226 | $1,799 |
| Novartis | 54 | $753 |
| Impulse Dynamics (USA) Inc. | 9 | $598 |
| Abiomed | 11 | $517 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $488 |
| United Therapeutics Corporation | 17 | $379 |
| Kestra Medical Technology Services, Inc. | 5 | $163 |
| Johnson & Johnson | 10 | $158 |
| Merck | 7 | $152 |
| Asahi Intecc USA, Inc. | 1 | $119 |
| Novo Nordisk | 4 | $89 |
| Amgen | 3 | $65 |
| Boehringer Ingelheim | 3 | $60 |
| Gilead | 2 | $45 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Cardiac Dimensions, Inc. | 1 | $41 |
| Vifor Pharma, Inc. | 2 | $40 |
| Lantheus Medical Imaging, Inc. | 1 | $34 |
| Altathera Pharmaceuticals LLC | 2 | $26 |
| AbbVie | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $15 |
How this compares
$469,824 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in la Jolla
- James Heywoodla Jolla$2.1M
- Kimberly Hongla Jolla$416K
- Rola Khedrakila Jolla$178K
- Ronald WittelesStanford$4.1M
- Eldrin LewisStanford$1.8M
- Richard WrightSanta Monica$1.7M
- Eric AdlerSan Diego$1.4M
- Mandar ArasSan Francisco$1.2M
- Dawn LombardoOrange$1.2M
- Alexander SandhuStanford$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.